Psychiatry Research
Volume 109, Issue 3 , Pages 297-302 , 15 April 2002

Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia

  • Xiang Yang Zhang

      Affiliations

    • Institute of Mental Health, School of Medicine, Peking University, Beijing 100083, PR China
    • Beijing Huilongguan Hospital, Beijing 100096, PR China
    • Corresponding Author InformationCorresponding author. Yale University School of Medicine, SHM B-267, Department of Psychiatry, 333 Cedar Street, New Haven, CT 06520-8066, USA. Tel.: +1-203-785-4510; fax: +1-203-785-7670
    • ,
  • Dong Feng Zhou

      Affiliations

    • Institute of Mental Health, School of Medicine, Peking University, Beijing 100083, PR China
    • ,
  • Cao Lian Yuan

      Affiliations

    • Beijing Huilongguan Hospital, Beijing 100096, PR China
    • ,
  • Pei Yan Zhang

      Affiliations

    • Beijing Huilongguan Hospital, Beijing 100096, PR China
    • ,
  • Gui Ying Wu

      Affiliations

    • Beijing Huilongguan Hospital, Beijing 100096, PR China
    • ,
  • Yu Cun Shen

      Affiliations

    • Institute of Mental Health, School of Medicine, Peking University, Beijing 100083, PR China

Received 2 April 2001 ,Revised 7 December 2001 ,Accepted 28 January 2002.

References 

  1. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, Parkinsonian side effects, and neuroendocrine response. American Journal of Psychiatry. 1999;156:294–298
  2. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry. 1997;58(Suppl. 10):28–36
  3. Casey DE. Side effect profiles of new antipsychotic agents. Journal of Clinical Psychiatry. 1996;57(Suppl. 11):40–45
  4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology. 1993;13:25–40
  5. Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research. 1998;81:51–55
  6. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskins J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica. 1992;85:295–305
  7. Coccaro EF, Kavoussi RJ. Neuropsychopharmacologic challenge in biological psychiatry. Clinical Chemistry. 1994;40:319–327
  8. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 1996;126:24–30
  9. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–483
  10. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapy. 2000;22:1085–1096
  11. Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology. 1993;112:461–466
  12. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs. 1998;10:209–222
  13. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics. 1988;244:685–693
  14. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology. 1981;72:184–187
  15. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. American Journal of Psychiatry. 2001;158:311–314
  16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  17. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 1996;124:2–34
  18. Kirkpatrick B, Buchanan RW, Maeda K, Carpenter WT, Jauch D, Tamminga CA. Effect of neuroleptic withdrawal on serum prolactin: a possible marker of receptor adaptation. Biological Psychiatry. 1989;26:131–138
  19. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology. 1999;19:57–61
  20. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clinical and Experimental Pharmacology and Physiology. 1992;19:603–606
  21. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics. 1988;247:661–670
  22. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 1994;151:825–835
  23. Markianos M, Hatzimanolis J, Lykouras L. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology. 1999;143:270–272
  24. Melkersson K, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. British Journal of Clinical Pharmacology. 2001;51:317–324
  25. Meltzer HY, Busch D, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Research. 1983;9:271–283
  26. Meltzer HY, Koenig JI, Nash JF, Gudelsky GA. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatrica Scandinavica. 1989;352(Suppl.):24–29
  27. Mohr P, Horacek J, Motlova L, Libiger J, Czobor P. Effects of haloperidol treatment on prolactin response to d-fenfluramine challenge in acute schizophrenia. Psychopharmacology. 1999;141:322–325
  28. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology. 2000;148:3–15
  29. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57–73
  30. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1:133–152
  31. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R—Patient Version 1.0 (SCID-P). Washington, DC: American Psychiatric Press; 1990;
  32. Van Putten T, Marder SR, Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. Journal of Clinical Psychopharmacology. 1991;11:357–361
  33. Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment—refractory schizophrenia. American Journal of Psychiatry. 1999;156:1374–1379
  34. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. American Journal of Psychiatry. 1992;7:163–165

PII: S0165-1781(02)00022-7

Psychiatry Research
Volume 109, Issue 3 , Pages 297-302 , 15 April 2002

Article Tools